B Cell Non Hodgkin Lymphoma clinical trials

Explore recruiting b cell non hodgkin lymphoma clinical trials.

Recruiting b cell non hodgkin lymphoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

B Cell Non Hodgkin Lymphoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Tisagenlecleucel versus standard of care in adult patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: A randomized, open label, phase III trial (BELINDA)

Netherlands, Spain, Norway, Italy, Germany, France +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Phase I/II Trial to Determine Persistence, Safety and Clinical Activity of Allogeneic CIK Cells Transduced with a Transposon CD19-chimeric Antigen Receptor (CARCIK-CD19) in Adult and Pediatric Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma and B-cell Chronic Lymphocytic Leukemia

Italy

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody®-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma

Spain, Sweden, Italy, Belgium, Finland, France +4 more

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Open-label dose-finding and dose-expansion study to evaluate the safety, expansion, persistence, and clinical activity of UCART20x22 in subjects with relapsed or refractory B-cell Non-Hodgkin Lymphoma (B-NHL)

Spain, France, Italy

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

An Open Label, Phase 2 Clinical Trial of MEN1703 as Monotherapy and in Combination with Glofitamab in Patients with Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)

Poland, France, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 1b/2 Study of JNJ-90014496 in Adult Participants with B-cell Non-Hodgkin Lymphoma

Spain, Netherlands, Germany, France, Denmark, Italy

Human Pharmacology (Phase I)- Other EU CTIS Study details

B Cell Non Hodgkin Lymphoma trials by city

B Cell Non Hodgkin Lymphoma in Toronto B Cell Non Hodgkin Lymphoma in Vancouver B Cell Non Hodgkin Lymphoma in Montreal B Cell Non Hodgkin Lymphoma in Calgary B Cell Non Hodgkin Lymphoma in Edmonton B Cell Non Hodgkin Lymphoma in Ottawa B Cell Non Hodgkin Lymphoma in Winnipeg B Cell Non Hodgkin Lymphoma in Quebec City B Cell Non Hodgkin Lymphoma in Hamilton B Cell Non Hodgkin Lymphoma in Kitchener B Cell Non Hodgkin Lymphoma in London B Cell Non Hodgkin Lymphoma in Halifax B Cell Non Hodgkin Lymphoma in New York B Cell Non Hodgkin Lymphoma in Los Angeles B Cell Non Hodgkin Lymphoma in Chicago B Cell Non Hodgkin Lymphoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease